Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Case Report, Endocrinol Diabetes Res Vol: 2 Issue: 1
A Case Report of Diabetic Ketoacidosis Associated with Multiple Risk Factors Including Dapagliflozin Use
| El-rifai M*, Poor D and Khaddash S | |
| Internal Medicine Department, St. Joseph Regional Medical Center, Paterson, USA | |
| Corresponding author : Mohammad El-rifai, MD
Internal Medicine department at St. Joseph Regional Medical Center. 703 Main St, Paterson, NJ 07503, USA Tel: 973-289-4979 E-mail: Elrifai3@yahoo.com |
|
| Received: January 06, 2016 Accepted: June 07, 2016 Published: June 12, 2016 | |
| Citation: El-rifai M, Poor D, Khaddash S (2016) A Case Report of Diabetic Ketoacidosis Associated with Multiple Risk Factors Including Dapagliflozin Use. Endocrinol Diabetes Res 2:1. doi:10.4172/2470-7570.1000114 |
Abstract
Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of antihyperglycemic agents that inhibit renal glucose reabsorption. This group of medications got more popular in diabetic management as it help to control the blood sugar level and it induce weight loss. However, FDA issued a warning of possible association between SGLT2 inhibitors usage and DKA after the reports of several euglycemic DKA cases associated with the use of SGLT2 inhibitors.
